CDC NCIRD Vaccine Administration Management System
Investment ID: 009-000453500
Overview
Program Title
CDC NCIRD Vaccine Administration Management System
Description
The Vaccine Administration Management System VAMS is a web-based application that tracks the administration and distribution of vaccinations, including emergency vaccine response e.g., COVID-19 and monkeypox and non-emergency vaccines.
Type of Program
Major IT Investments
Multi-Agency Category
Not Applicable
Associated Websites
https://vams.cdc.gov/
Investment Detail
The VAMS application supports jurisdictions' daily in the goal of vaccinating the population and managing the inventory of the vaccination. In FY2022 VAMS onboarded new jurisdictions and continued COVID-19 and influenza vaccinations. Some statistics include:
2 Jurisdictions, 6 Government Entities, and 2 hospital/pharmacy systems are currently using VAMS.
58.5k of clinic users who we communicate with in monthly newsletters
11.4M Cumulative total COVID-19 doses logged in VAMS
5.4M total 2nd dose vaccination events
30k total 3rd dose vaccination events
900k booster dose vaccination events
4k Cumulative total influenza vaccines logged in VAMS
The VAMS application is unique as it needs to continually evolve and adjust as the response to the pandemic shifts. To keep up with the frequently changing needs of the customer, the VAMS team works daily with various stakeholders at CDC as well as Jurisdictions and Providers.
When evaluating the economic performance and cost effectiveness of VAMS over its entire life cycle, the cumulative short-term expense of owning and deploying VAMS is expected to be approximately $69.1M. Given the dynamic and rapidly changing pandemic environment, current costs are consistent with the FY2022 O&M baseline and are in line with the cumulative lifecycle cost. FY2020 and FY2021 DME costs of $27M are accounted for building out VAMS to a robust, defensible, functioning, and compliant state. FY2022 costs are reflective of the O&M steady-state phase of the Investment, and the costs are mainly driven by the increase in States onboarded, trainings, multi-phased deployments and releases to name a few. All of which reinforced and improved mission critical metrics across the board. At the moment, VAMS is slated to cost approximately $10.9M for FY2022.
2 Jurisdictions, 6 Government Entities, and 2 hospital/pharmacy systems are currently using VAMS.
58.5k of clinic users who we communicate with in monthly newsletters
11.4M Cumulative total COVID-19 doses logged in VAMS
5.4M total 2nd dose vaccination events
30k total 3rd dose vaccination events
900k booster dose vaccination events
4k Cumulative total influenza vaccines logged in VAMS
The VAMS application is unique as it needs to continually evolve and adjust as the response to the pandemic shifts. To keep up with the frequently changing needs of the customer, the VAMS team works daily with various stakeholders at CDC as well as Jurisdictions and Providers.
When evaluating the economic performance and cost effectiveness of VAMS over its entire life cycle, the cumulative short-term expense of owning and deploying VAMS is expected to be approximately $69.1M. Given the dynamic and rapidly changing pandemic environment, current costs are consistent with the FY2022 O&M baseline and are in line with the cumulative lifecycle cost. FY2020 and FY2021 DME costs of $27M are accounted for building out VAMS to a robust, defensible, functioning, and compliant state. FY2022 costs are reflective of the O&M steady-state phase of the Investment, and the costs are mainly driven by the increase in States onboarded, trainings, multi-phased deployments and releases to name a few. All of which reinforced and improved mission critical metrics across the board. At the moment, VAMS is slated to cost approximately $10.9M for FY2022.